How to buy Zoetis shares | ZTS historical share price and analysis

How to buy Zoetis shares

Own Zoetis shares in just a few minutes.

Zoetis logo

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Zoetis Inc (ZTS) is a leading drug manufacturers-specialty & generic business with stocks listed in the US. It opened the day at US$169.58 after a previous close of US$168.74. During the day the price has varied from a low of USD168.88 to a high of USD171.16. The latest price was USD170.15 (25 minute delay). Zoetis is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in Zoetis

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Zoetis. Find the share by name or ticker symbol: ZTS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Zoetis reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Zoetis, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Zoetis. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Zoetis share price

Use our graph to track the performance of ZTS stocks over time.

Zoetis shares at a glance

Information last updated 2021-04-21.
OpenUS$169.58
HighUS$171.16
LowUS$168.88
CloseUS$170.15
Previous closeUS$168.74
Change US$1.41
Change % 0.8356%
Volume 1,165,087
Information last updated 2021-04-16.
52-week rangeUS$120.9908 - US$176.3666
50-day moving average US$155.1877
200-day moving average US$160.5884
Target priceUS$186.67
PE ratio 48.3772
Dividend yield US$0.8 (0.49%)
Earnings per share (TTM) US$3.42

Compare share trading platforms to buy stock

Data updated regularly
Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
US shares
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Zoetis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Zoetis price performance over time

Historical closes compared with the last close of $170.15

1 month (2021-03-23) 9.04%

Is Zoetis under- or over-valued?

Valuing Zoetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zoetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Zoetis's P/E ratio

Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, Zoetis shares trade at around 48x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Zoetis's PEG ratio

Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.1123. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Zoetis's EBITDA

Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$2.7 billion (£1.9 billion).

The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure a its profitability.

Zoetis financials

Revenue TTM US$6.7 billion
Operating margin TTM 34.47%
Gross profit TTM US$4.6 billion
Return on assets TTM 11.43%
Return on equity TTM 50.49%
Profit margin 24.54%
Book value 7.929
Market capitalisation US$78.6 billion

TTM: trailing 12 months

Shorting Zoetis shares

There are currently 4.7 million Zoetis shares held short by investors – that's known as Zoetis's "short interest". This figure is 45.5% up from 3.2 million last month.

There are a few different ways that this level of interest in shorting Zoetis shares can be evaluated.

Zoetis's "short interest ratio" (SIR)

Zoetis's "short interest ratio" (SIR) is the quantity of Zoetis shares currently shorted divided by the average quantity of Zoetis shares traded daily (recently around 2.3 million). Zoetis's SIR currently stands at 2.01. In other words for every 100,000 Zoetis shares traded daily on the market, roughly 2010 shares are currently held short.

However Zoetis's short interest can also be evaluated against the total number of Zoetis shares, or, against the total number of tradable Zoetis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zoetis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Zoetis shares in existence, roughly 10 shares are currently held short) or 0.0099% of the tradable shares (for every 100,000 tradable Zoetis shares, roughly 10 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zoetis.

Find out more about how you can short Zoetis stock.

Zoetis's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zoetis.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Zoetis's total ESG risk score

Total ESG risk: 28.6

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zoetis's overall score of 28.6 (as at 12/31/2018) is nothing to write home about – landing it in it in the 49th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Zoetis is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Zoetis's environmental score

Environmental score: 2.72/100

Zoetis's environmental score of 2.72 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Zoetis's social score

Social score: 13/100

Zoetis's social score of 13 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Zoetis's governance score

Governance score: 8.87/100

Zoetis's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Zoetis is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Zoetis's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Zoetis scored a 1 out of 5 for controversy – the highest score possible, reflecting that Zoetis has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Zoetis Inc was last rated for ESG on: 2019-01-01.

Total ESG score 28.6
Total ESG percentile 49.38
Environmental score 2.72
Environmental score percentile 1
Social score 13
Social score percentile 1
Governance score 8.87
Governance score percentile 1
Level of controversy 1

Zoetis share dividends

24%

Dividend payout ratio: 24.16% of net profits

Recently Zoetis has paid out, on average, around 24.16% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.61% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zoetis shareholders could enjoy a 0.61% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $0.8 per share.

While Zoetis's payout ratio might seem low, this can signify that Zoetis is investing more in its future growth.

Zoetis's most recent dividend payout was on 31 May 2021. The latest dividend was paid out to all shareholders who bought their shares by 19 April 2021 (the "ex-dividend date").

Zoetis share price volatility

Over the last 12 months, Zoetis's shares have ranged in value from as little as US$120.9908 up to US$176.3666. A popular way to gauge a stock's volatility is its "beta".

ZTS.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.615. This would suggest that Zoetis's shares are less volatile than average (for this exchange).

Zoetis overview

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site